A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer
研究概览
详细说明
OGX-011 is an experimental drug that has been shown to increase the effectiveness of commonly used cancer therapies such as chemotherapy, radiation and hormone therapy in several kinds of cancer types in animals. OGX-011 is being studied in the treatment of cancer patients in combination with chemotherapy. In humans, OGX-011 in combination with hormone therapy has been shown to decrease the tissue levels of a protein called clusterin, which can be overproduced in cancer cells. Clusterin has been found to block cell death and makes cells more resistant to cancer therapy. Gemcitabine (GEM), cisplatin (CIS) and carboplatin (CARB) have been approved by Health Canada and the Food and Drug Administration in the United States for the treatment of patients with lung cancer.
OGX-011 was administered as a 2-hr intravenous (IV) infusion on Days -7, -5, and -3 prior to Cycle 1, then weekly on Days 1, 8, 15 of each 21-day cycle; GEM was infused IV after OGX-011 on Days 1 and 8; either CIS or CARB was infused IV after GEM on Day 1 of each cycle. Six cycles of treatment were planned. Most patients received OGX-011 at 640 mg, but 3 patients received OGX-011 at 480 mg dose; OGX-011 dose groups were combined due to the small number of patients who received 480 mg.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大
- Tom Baker Cancer Centre
-
-
British Columbia
-
Surrey、British Columbia、加拿大
- BC Cancer Agency, Fraser Valley Centre
-
Vancouver、British Columbia、加拿大
- BC Cancer Agency, Vancouver Center
-
-
Newfoundland and Labrador
-
St. Johns、Newfoundland and Labrador、加拿大
- Dr. H. Bliss Murphy Cancer Center
-
-
Ontario
-
Barrie、Ontario、加拿大
- Royal Victoria Hospital of Barrie
-
London、Ontario、加拿大
- London Regional Cancer Centre
-
Ottawa、Ontario、加拿大
- Ottawa Hospital
-
Toronto、Ontario、加拿大
- Toronto Sunnybrook Regional Cancer Center
-
-
Quebec
-
Ste-Foy、Quebec、加拿大
- Hôpital Laval
-
-
-
-
California
-
Los Angeles、California、美国、90033
- LAC-USC Medical Center
-
Los Angeles、California、美国、90033
- University of Southern California Norris
-
-
New York
-
Albany、New York、美国、12208
- New York Oncology Hematology
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health and Science University
-
-
South Carolina
-
Greenville、South Carolina、美国、29605
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas、Texas、美国、75246
- Mary Crowley Medical Research Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria
- Patients must have a histologically or cytologically confirmed diagnosis of NSCLC and must not have had chemotherapy or biological therapy for their disease.
- Stage IIIB (N3 and/or pleural or pericardial effusion) or IV disease that is not amenable to either surgery or radiation therapy of curative intent.
- Life expectancy of ≥ 12 weeks
- If patient has had prior radiation therapy: lesion(s) used for determination of response was not previously irradiated or has increased in size since the completion of radiotherapy; and patient has recovered from any toxicity from the radiotherapy.
- Radiotherapy to lesion(s) used for determination of response was completed at least 6 weeks prior to treatment; radiotherapy to other sites was completed at least 2 weeks prior to treatment.
- At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors [RECIST] (at least 10 mm in longest diameter by spiral computed tomography [CT] scan, or at least 20 mm by standard techniques).
- ECOG status must be ≤ 1
Exclusion Criteria
- Prior chemotherapy or biological therapy (approved or experimental) for NSCLC, including adjuvant and neoadjuvant treatment.
- Presence of central nervous system (CNS) metastases, unless the patient has completed successful local therapy for CNS metastases, with the exception of leptomeningeal disease for which patients will be excluded. Patients must be off corticosteroids for at least 21 days prior to starting treatment.
- Second primary malignancy (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin cancers, clinically localized prostate cancer, superficial bladder cancer or other malignancy treated at least 3 years previously with no evidence of recurrence).
- Patients eligible for combined modality therapy with curative intent as defined by the combination of chemotherapy, radiation therapy and/or surgery. (This criteria is intended to exclude patients with stage IIIB disease, as defined by the presence of N3 nodal status, who have been reported to have cure rates as high as 10% when treated with combined modality therapy.)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen
大体时间:Based on assessments at baseline and after Cycles 2, 4, and 6. All subjects were followed for survival for a minimum of 3 years after the first dose of OGX-011 or until death.
|
Per RECIST Criteria V 1.0 and based on radiographic evaluations a subject was defined as having an objective response (OR) if the subject achieved either a confirmed partial response (PR) or confirmed complete response (CR). The evaluations were conducted after every two cycles of treatment for a maximum of 6 cycles. CR: disappearance of clinical/radiological evidence of tumor. PR: >= 30% decrease in the sum of the longest diameter of target lesions. SD: did not fulfill the criteria for CR or PR but not progressive disease. |
Based on assessments at baseline and after Cycles 2, 4, and 6. All subjects were followed for survival for a minimum of 3 years after the first dose of OGX-011 or until death.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression-free Survival
大体时间:All subjects were followed for a minimum of 3 years after the first dose of OGX-011 or until death.
|
Progression-free survival (PFS) was defined as time from first treatment with OGX-011 to documented evidence of disease progression or date of death.
For subjects without disease progression based on RECIST who initiated subsequent anti-cancer therapy, date of progression was defined as date of initiating new cancer treatment.
PFS was censored as of the date of first OGX-011 dose for subjects who failed to return for assessments after screening.
For subjects who were still alive and without progressive disease at the time of data cut-off, PFS was censored at date of last disease assessment.
|
All subjects were followed for a minimum of 3 years after the first dose of OGX-011 or until death.
|
Overall Survival
大体时间:All subjects were followed for a minimum of 3 years after the first dose of OGX-011 or until death.
|
Overall survival was defined as time from date of first treatment with OGX-011 to the date of death from any cause.
Overall survival was censored at date of last contact for subjects who were still alive at end of study.
|
All subjects were followed for a minimum of 3 years after the first dose of OGX-011 or until death.
|
Effect of OGX-011 on Serum Clusterin Levels
大体时间:Blood samples were collected at baseline and prior to infusion on Cycle 2 Day 1 and Cycle 3 Day 1
|
To measure the effect of OGX-011 on serum clusterin levels.
The drug substance, OGX-011, is an antisense product designed to bind to clusterin mRNA, resulting in the inhibition of the production of human clusterin protein.
Therefore, serum clusterin levels were expected to decrease.
|
Blood samples were collected at baseline and prior to infusion on Cycle 2 Day 1 and Cycle 3 Day 1
|
Cmax of OGX-011
大体时间:Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
Cmax is a plasma pharmacokinetic parameter that is defined as the maximum observed concentration of drug substance in plasma.
|
Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
t1/2 of OGX-011
大体时间:Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
Plasma half life of OGX-011
|
Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
AUC-0-last
大体时间:Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
AUC-0-last is the area under the plasma concentration time curve from time 0 to the last last time point (23.5 hrs)
|
Blood samples were collected as follows. Cycle 1; Day 1: pre-dose, 2 h (EOI), 0.5 h, 1 hr, 1.5 h, 2.5 h, 4 h, 6.5 h and 23.5 h post end of OGX-011 infusion, Day 22: pre-dose Cycle 2.
|
合作者和调查者
调查人员
- 首席研究员:Janessa Laskin, M.D.、BCCA, Vancouver Clinic
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
custirsen sodium的临床试验
-
Achieve Life SciencesTeva Branded Pharmaceutical Products R&D, Inc.完全的
-
Sanofi完全的静脉血栓栓塞症美国, 加拿大, 俄罗斯联邦, 乌克兰, 火鸡, 印度, 墨西哥, 埃及, 立陶宛, 哥伦比亚, 秘鲁, 大韩民国, 智利, 白俄罗斯, 中国, 南非